Balancing risks versus benefits in drug therapy decisions

Clinical Therapeutics

Volumn 20, Issue SUPPL. C, 1998, Pages

  Lasagna, Louis ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse reactions; Drug benefits; Drug regulation; Individualized therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; DIETHYLENE GLYCOL; DRUG; SULFANILAMIDE; THALIDOMIDE;

DRUG APPROVAL; DRUG CHOICE; DRUG CONTAMINATION; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH EDUCATION; HUMAN; MEDICAL DECISION MAKING; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 0032432132     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80010-6     Document Type: Article

References (7)

1. Study cites adverse medication reactions in many patient deaths. The Boston Globe, April 15, 1998, p. A8.
2. Lazarus J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA. 1998;279: 1200-1205.
3. Sinclair U. The Jungle. New York: Heritage Press; 1965.
4. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21: 247-254.
5. Bakke OM, et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective. Clin Pharmacol Ther. 1995;58:108-117.
6. Hippocrates. Epidemics. Book I, Sect. 12. Translation by Jones WHS. London: W. Heinemann; 1923.
7. Dans AL, Dans LF, Guyatt GH, Richardson S. User's guides to the medical literature-XIV. How to decide on the applicability of clinical trial results to your patient. JAMA. 1998;279:545-549.